Q-omics provides the consensus-scored SYT12 profile across patient tissues and cancer cell-line models. SYT12 expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, SYT12 is differentially expressed in 11, with the highest sampling consensus in THCA. Additionally, SYT12 RNA expression shows 15,373 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight ACC, THCA, and THYM as cancer lineages where SYT12 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SYT12 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SYT12 survival associations across molecular data types. SYT12 RNA expression shows survival associations in the most cancer types (28), followed by mutation status (3) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SYT12 RNA expression–survival associations across cancer types. High SYT12 expression shows unfavorable associations in ACC, PAAD, UCEC and KIRC, but favorable associations in SKCM and KIRP. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for SYT12 RNA expression.
This table summarizes SYT12 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for SYT12. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SYT12 shows lower tumor expression in KICH and higher tumor expression in THCA, LUAD, KIRP, KIRC and LUSC. The THCA box plot shows higher SYT12 RNA expression in tumor versus normal tissue (log2 FC = +5.013, t-test p < 0.001).
This table shows molecular features associated with SYT12 in patient tissues and cancer cell lines. In patient samples, SYT12 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, SYT12 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Myeloma and BREAST.
